Skip to main content

"A novel multi-functional elastin-like recombinant hydrogel for the prevention of scar tissue formation following a myocardial infarction: ""ELR-SCAR"""

Objective

The ELR SCAR project aims to complete preclinical validation of a novel biomaterial, an elastin-like recombinant (ELR) hydrogel, to prevent scar tissue formation in the heart following myocardial infarction (MI), commonly called a heart attack. MI is the endpoint of ischaemic heart disease (IHD). In Europe, the highest rates of IHD worldwide equal ~26.5 million patients. Standards of care interventions after MI have serious limitations in treatment efficacy (many patients are still at risk of developing heart failure) and patient safety. There is a clear medical need for new treatment solutions that prevent scar tissue formation and irreversible cardiac remodelling. Our robust preclinical dataset so far indicates that the ELR hydrogel has this promising functionality via multiple unique characteristics: it provides selective cell adhesion to the endocardium, providing a barrier to scar tissue formation; it offers high biospecificity to the ischaemic microenvironment, and it has an enhanced biodegradability, allowing for safe disintegration in the body. To facilitate endocardial delivery of the ELR hydrogel, we will develop a minimally invasive endocardial catheter in this project. Both components (hydrogel + catheter) will be advanced to the preparedness level for a first-in-human (FIH) validation study for the application as therapeutic intervention post-MI (to be performed after the project). In addition, we will develop the regulatory and IPR strategies in preparation for this clinical validation step. Considering the high societal impact of ischaemic heart disease (IHD) and MI, we will also develop a solid health economic evaluation of possible savings and patient benefits. ELR-SCAR will transform and fundamentally improve clinical practice, resulting in reducing the enormous burden that MI and its leading cause, IHD, place on society and the individual patient.

Coordinator

NATIONAL UNIVERSITY OF IRELAND GALWAY
Net EU contribution
€ 1 245 836,00
Address
University Road
H91 Galway
Ireland

See on map

Region
Ireland Eastern and Midland Dublin
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,25

Participants (7)

TECHNICAL PROTEINS NANOBIOTECHNOLOGY SL
Spain
Net EU contribution
€ 949 998,73
Address
Paseo De Belen 11
47011 Valladolid

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Castilla y León Valladolid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
BOSTON SCIENTIFIC LIMITED
Ireland
Net EU contribution
€ 879 145,00
Address
Ballybrit Business Park
H91 Galway

See on map

Region
Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS
Lithuania
Net EU contribution
€ 317 412,50
Address
A Mickeviciaus Gatve 9
44307 Kaunas

See on map

Region
Lietuva Vidurio ir vakarų Lietuvos regionas Kauno apskritis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
HEMEX GERMANY GMBH
Germany
Net EU contribution
€ 393 125,00
Address
Marie-curie-strasse 8
79539 Lorrach

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Baden-Württemberg Freiburg Lörrach
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH
Poland
Net EU contribution
€ 250 625,00
Address
Ul. Poniatowskiego 15
40 055 Katowice

See on map

Region
Makroregion południowy Śląskie Katowicki
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
CARDIOVASCULAR RESEARCH CENTER AALST VZW
Belgium
Net EU contribution
€ 252 187,50
Address
Moorselbaan 164
9300 Aalst

See on map

Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Aalst
Activity type
Research Organisations
Other funding
€ 0,00
Catalyze B.V.
Netherlands
Net EU contribution
€ 174 062,50
Address
Joop-geesinkweg 167
1114 AB Amsterdam-duivendrecht

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00